MBX Microbix Biosystems

Microbix Participating in COVID-19 Virtual Conference

Microbix Participating in COVID-19 Virtual Conference

Presentation and Panel Participation at Adelaide Capital Event on April 23  

MISSISSAUGA, Ontario, April 21, 2020 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it will be participating in the “Virtual COVID & Healthcare Mini Conference” being hosted by Adelaide Capital on April 23 from 12:00-5:00 PM ET.

The conference will showcase the contributions that Canadian companies are making to help fight the coronavirus pandemic. Microbix will be discussing its longstanding work in providing the biological core of many existing diagnostic tests for infectious diseases, including for multiple respiratory viruses and bacteria. Additionally, Microbix will discuss how its Quality Assessment Products (QAPs™) can help ensure the accuracy of diagnostic tests, including tests for respiratory viruses and, in particular, about its important new REDx™FLOQ® SARS-CoV-2 swab-based and REDx™ SARS-CoV-2 liquid-format QAPs.

It has been widely reported that the recently-deployed tests for the virus causing COVID-19 disease are providing results of questionable accuracy – sometimes giving “false negative,” or “false positive” results.  Microbix’s new QAPs are designed to increase the reliability of testing for the SARS-CoV-2 coronavirus.

The conference will consist of a series of 20-minute corporate presentations, a panel discussion of critical pandemic-related issues, and a keynote presentation by Mr. Eden Rahim of Next Edge Capital. Mr. Rahim is a highly-respected life-sciences portfolio manager and his presentation at the conference is entitled, “Signal from the Noise: A compass to finding COVID-19 investment opportunities.”

To attend the Virtual COVID & Healthcare Mini Conference, RSVP via hyperlink (), or by inputting /webinar/register/WN_rbV3mis6RIyQG7WFVTx2cA into your browser. The conference will also be live streamed to Adelaide Capital’s YouTube Channel ( and a replay will also be posted. Recently, information about Microbix has been posted to the Adelaide Capital YouTube Channel and the Microbix website, including an interview on COVID-19 QAPs with Ken Hughes, COO of Microbix, and a CEO corporate Webinar presentation.

Kindly note that the conference is in support of the HandSan Project. The HandSan Project is providing free 50 to 80 mL bottles of 70 to 80% ethanol hand sanitizer to high-need individuals in the Ottawa area. Further information about the HandSan Project is available from /

Adelaide Capital is a full-service Investor Relations firm that provides a unique and powerful perspective on Canadian public companies and a re-engineered business model. Adelaide’s extensive capital markets experience allows it to go deeper, strategically assessing each client and tailoring a plan that charts the best path to business success as a publicly-listed company. Specializing in small and mid-capitalization companies, its offerings are enhanced by a truly formidable factor – personal relationships with an extensive and deeply-valued network of investors across North America and around the world.

About Microbix Biosystems

Microbix develops proprietary biological and technology solutions for human health and well-being, with approximately 80 skilled employees and sales now usually exceeding $1 million per month on average. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure quality control of clinical diagnostic tests. Microbix antigens and QAPs are sold to many customers worldwide, at present primarily to multinational diagnostics companies and laboratory accreditation organizations.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots.

Microbix is a publicly-traded company, listed on the Toronto Stock Exchange and headquartered in Mississauga, Ontario, Canada.

Forward-Looking Information

This news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of AdCap, Next Edge, HandSan, or the conference, the COVID-19 QAPs, the utility or consequences of use of the COVID-19 QAPs, references to external collaborators and regulatory processes, Microbix’s business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its corporate presentation, regulatory compliance and approvals, sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward looking information is inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company’s judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.

Please visit  or  for recent Microbix news and filings.

For further information, please contact Microbix at:

 
Cameron Groome, CEO

(905) 361-8910
Jim Currie, CFO

(905) 361-8910
Deborah Honig, Investor Relations

Adelaide Capital Markets

(647) 203-8793   

Copyright © 2020 Microbix Biosystems Inc.

Microbix®, Kinlytic®, PROCEEDx™, QAPs™, and REDx™ Controls are trademarks of Microbix Biosystems Inc.

COPAN® and FLOQSwab® are trademarks of COPAN Italia SPA

REDx™FLOQ® is a trademark of Microbix Biosystems Inc. in cooperation with COPAN Italia SPA

EN
21/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Microbix Biosystems

 PRESS RELEASE

Microbix Schedules Release of Results for Q3 Fiscal 2025 Results Relea...

Microbix Schedules Release of Results for Q3 Fiscal 2025 Results Release and Webinar Discussion on Morning of August 14, 2025 MISSISSAUGA, Ontario, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its third quarter of fiscal 2025 ended June 30, 2025 (“Q3 2025”) prior to the start of trading on August 14, 2025. At 10:00 AM ET that day, Microbix intends to hold a webi...

 PRESS RELEASE

Microbix Launches QUANTDx™ Characterized Reference Materials

Microbix Launches QUANTDx™ Characterized Reference Materials New Product Line Supporting Diagnostic Assay Manufacturers MISSISSAUGA, Ontario, July 29, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QUANTDx™, a new product line of well-characterized reference materials designed to support the development and validation of diagnostic assays. QUANTDx is being launched at ADLM 2025, the conference of the Association for Diagnostic & Laboratory Medicine being held...

 PRESS RELEASE

Microbix Exhibiting & Presenting at ADLM

Microbix Exhibiting & Presenting at ADLM Microbix & API Presenting H5N1 Pandemic Preparedness Results MISSISSAUGA, Ontario, July 24, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending, exhibiting, and presenting at the Association for Diagnostic & Laboratory Medicine (“ADLM”) conference taking place in Chicago, Illinois July 28 to 31, 2025. At ADLM, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of many infecti...

 PRESS RELEASE

Microbix & Bulgaria’s NCIPD Execute Supply Agreement

Microbix & Bulgaria’s NCIPD Execute Supply Agreement Microbix to Develop New Products using NCIPD Organism Collection MISSISSAUGA, Ontario and SOFIA, Bulgaria, July 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and the National Center for Infectious and Parasitic Diseases of Bulgaria (“NCIPD”), announce an agreement whereby NCIPD will supply a portfolio of pathogen seedstocks for production of Microbix quality assessment products (“QAPs™”). Following detailed discussions and a meeting ...

 PRESS RELEASE

Microbix Attending & Presenting at Asia Pacific POC 2025

Microbix Attending & Presenting at Asia Pacific POC 2025 Showcasing Global Utility of its QAPs at Point-of-Care Testing Conference MISSISSAUGA, Ontario, June 17, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is attending and presenting at the 2nd Asia Pacific Conference on Point of Care Testing for Infectious Diseases, taking place in Bangkok, Thailand from 19 to 21 June, 2025 (“POC 2025”). At POC 2025, Microbix will be presenting a poster of results about the global utility...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch